Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Discovery"
DOI: 10.1158/2159-8290.cd-22-1074
Abstract: Cancer-specific neoantigens created in the form of a covalent drug conjugated to a fragment of an intracellular oncoprotein selectively mark drug-resistant cancer cells for killing with bispecific T-cell engagers. read more here.
Keywords: inhibitors targeted; neoantigens covalent; covalent inhibitors; mhc restricted ... See more keywords
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.00417
Abstract: The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using… read more here.
Keywords: dehydrogenase; dehydrogenase inhibitors; mutant isocitrate; isocitrate dehydrogenase ... See more keywords
RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24010266
Abstract: The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin family that is overexpressed in several cancers. RAGE is highly expressed in the lung, and its expression increases proportionally at the… read more here.
Keywords: inhibitors targeted; review; end products; rage ... See more keywords